Diabetic Macular Edema and Maculopathy: Pathophysiology, Symptoms, and Modern Treatments

Diabetic maculopathy encompasses retinal changes at the macula due to diabetes, primarily diabetic macular edema (DME)—the leading cause of vision loss in working-age adults with diabetes.

Pathophysiology

  • Chronic hyperglycemia → pericyte loss, basement membrane thickening, endothelial dysfunction → capillary leakage.
  • VEGF upregulation → vascular hyperpermeability → fluid accumulation in outer plexiform/inner nuclear layers (cystoid edema).
  • Ischemia → capillary non-perfusion → cotton wool spots, microaneurysms.

Classification

  • Center-involved DME (CI-DME): Edema involves foveal center (worse prognosis).
  • Non-center-involved: Better visual prognosis.
  • Diffuse vs. focal: Diffuse = widespread capillary leakage; focal = discrete microaneurysms.

Symptoms

  • Blurred/distorted central vision (metamorphopsia)
  • Difficulty reading, recognizing faces
  • Color desaturation
  • Often asymptomatic early—screening critical.

Treatment

  • Anti-VEGF (intravitreal): Aflibercept, ranibizumab, faricimab (first-line for CI-DME). Loading dose monthly ×3–6, then treat-and-extend.
  • Corticosteroids: Dexamethasone implant (Ozurdex), fluocinolone acetonide (Iluvien)—for pseudophakic or refractory; cataract/IOP risk.
  • Laser photocoagulation: Focal/grid for non-CI-DME; less used now.
  • Systemic: Glycemic control, BP/lipid management, SGLT2i/GLP-1 RA.

Screening

Regular dilated eye exams (annually or per ETDRS guidelines) enable early intervention and vision preservation. DME is treatable—especially when caught early.

Diabetes - Related Articles